Skip to main content

Table 1 Patient characteristics

From: Association of neutrophil-to-lymphocyte ratio with severe radiation-induced mucositis in pharyngeal or laryngeal cancer patients: a retrospective study

  

Radiotherapy-induced mucositis

Grade 1&2

Grade 3

  

N = 60

N = 39

Characteristic

Category

N

%

N

%

Sex

Male

56

93

36

92

Female

4

7

3

8

Age

Median (25–75% tile)

65.0 (59.5–72.0)

66.0 (63.0–71.5)

BMI (kg/m2)

Median (25–75% tile)

21.6 (18.7–24.0)

21.1 (19.3–24.3)

Smoking (pack-years)

Median (25–75% tile)

29.6 (15.0–42.9)

40.0 (17.5–63.8)

EOCG PS

0

27

45

21

54

1

25

42

17

44

2

6

10

1

3

3

2

3

0

0

Diabetes mellitus

Without

47

78

32

82

With

13

22

7

18

Primary tumor location

Hypopharynx

52

87

33

85

Larynx

8

22

6

15

Stage

1

3

5

0

0

2

7

12

6

15

3

11

18

9

23

4

39

65

24

62

Concomitant chemoradiotherapy

Radiotherapy alone

9

15

2

5

 

BRT

11

18

3

8

 

CRT

40

67

34

87

Total radiation dose (Gy)

Median (25–75% tile)

70.0 (63.0–70.0)

70.0 (66.0–70.0)

Radiotherapy method

IMRT

24

40

19

49

3D-CRT

36

60

20

51

Radiation field laterality

Bilateral

59

98

38

97

Lateral

1

2

1

3

Completion of radiotherapy

Completion

55

92

35

90

Discontinuation

3

5

2

5

Treatment pause

2

3

2

5

NLR

Median (25–75% tile)

2.6 (2.0–4.7)

4.2 (2.1–11.5)

NLR < 5

 

46

77

23

59

NLR > 5

 

14

23

16

41

albumin (g/dL)

Median (25–75% tile)

3.7 (3.5–4.2)

3.8 (3.5–4.1)

Hemoglobin (mg/dL)

Median (25–75% tile)

13.1 (11.9–14.1)

13.3 (11.6–14.4)

Urea nitrogen (mg/dL)

Median (25–75% tile)

13 (11–17)

14 (12–19)

Creatinine (mg/dL)

Median (25–75% tile)

0.76 (0.67–0.92)

0.78 (0.68–0.92)

  1. Abbreviations: BMI Body mass index, EOCG PS Eastern Cooperative Oncology Group performance status, NLR Neutrophil-to-lymphocyte ratio, BRT Bioradiotherapy (cetuximab with radiotherapy), CRT Chemotherapy (cisplatin or carboplatin with radiotherapy), IMRT Intensity-modulated radiotherapy, and 3D-CRT Three-dimensional conformal radiotherapy